A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations

This study will be an open-label, randomized, 4-period, 4-treatment, single-dose crossover study in healthy participants. Participants will receive one single dose of AZD5004 at the beginning of each of the four Treatment Periods, and a total of 4 doses of AZD5004. Three different formulations (F1, F3, and F4) will be used across the Treatment Periods. The study comprises of total four treatment periods. * A Screening Period of maximum 27 days. Four Treatment Periods of 7 days each. * Treatment Period 1 (Day -1 to Day 6) * Treatment Period 2 (Day 7 to Day 13) * Treatment Period 3 (Day 14 to Day 20) * Treatment Period 4 (Day 21 to Day 27) * A final Follow-up Visit within 7 to 10 days after the last study intervention administration (Day 22 of Treatment Period 4). The treatments are as follows: * Treatment 1: Single dose of AZD5004 in Formulation 1 (F1) -fasted * Treatment 2: Single dose of AZD5004 in Formulation 4 (F4) -fasted * Treatment 3: Single dose of AZD5004 in F4- fed * Treatment 4: Single dose of AZD5004 in Formulation 3 (F3) - fasted Participants will be randomized equally to one of the following treatment sequences: * Treatment Sequence A: F1, F4, F4 (fed), F3 * Treatment Sequence B: F4, F4 (fed), F3, F1 * Treatment Sequence C: F4 (fed), F3, F1, F4 * Treatment Sequence D: F3, F1, F4, F4 (fed)